Close
FINDING CURES TOGETHER<sup>SM</sup>

AACR Announces New Journal, Blood Cancer Discovery

Now accepting submissions for publication
8/1/2019

PHILADELPHIA — The American Association for Cancer Research (AACR) is launching a new journal, Blood Cancer Discovery. The journal will be the ninth in the AACR’s prestigious portfolio of scientific publications, including the highly cited journal, Cancer Discovery

“Hematologic malignancies account for about 10 percent of cancer cases and 9 percent of cancer deaths in the United States each year,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “By launching Blood Cancer Discovery, the AACR is enhancing its efforts to support the exchange of information in the exciting field of hematologic malignancies research. This new AACR journal will capture the most significant work in the field and inspire new thinking about this complex set of disorders. It is our hope that, through this new publication outlet, we will accelerate the pace of scientific discovery and lead to innovative breakthroughs in patient care.”

Blood Cancer Discovery will feature high-impact, peer-reviewed articles describing major advances in basic, translational, and clinical research on all subtypes of leukemia, lymphoma, myeloma, and associated diseases. The journal will provide a new platform for the dissemination of pace-setting advances generated by the worldwide community of blood cancer researchers and physician-scientists. 

Taking the helm as founding Editors-in-Chief will be Riccardo Dalla-Favera, MD, and Kenneth C. Anderson, MD, both distinguished international leaders in the field of hematologic oncology. They will work with an editorial board comprised of world-renowned experts to curate leading blood cancer research studies from labs and clinics all over the world for inclusion in this monthly journal. 

“The study of hematologic malignancies has served as the foundation for modern cancer treatments like chemotherapy and targeted therapy,” said Dalla-Favera. “Blood Cancer Discovery will offer an optimal outlet for researchers to publish novel science on blood cancers with the potential to influence the treatment of other cancers in the future.” 

Anderson added, “We anticipate that Blood Cancer Discovery will become the premier setting for outstanding hematologic malignancies research and will bring about improved treatment options and outcomes for blood cancer patients all over the world.” 

Dalla-Favera is director of the Institute for Cancer Genetics at Columbia University and serves as professor of pathology and cell biology, microbiology and immunology, and genetics and development. He is an elected Fellow of the AACR Academy and recipient of the 2017 AACR G.H.A. Clowes Memorial Award. He is also a member of the National Academy of Medicine and the National Academy of Science. His work focuses on the pathogenesis of cancers derived from B lymphocytes, including the testing of novel therapeutic approaches for their ability to target newly discovered genetic lesions and cellular pathways altered in tumors. These discoveries have led to the development of diagnostic tests that are now being evaluated in clinical trials. He earned his medical degree from the University of Milan Medical School and completed a fellowship at the National Cancer Institute.

Anderson is program director at the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute and Kraft Family Professor of Medicine at Harvard Medical School. He is an elected Fellow of the AACR Academy and recipient of the 2007 AACR-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research. He is also a member of the National Academy of Medicine. Over the last three decades, Anderson has focused his laboratory and clinical research studies on multiple myeloma, developing laboratory and animal models to better understand the biological mechanisms of the disease. These findings have been translated into clinical trials that culminated in U.S. Food and Drug Administration approval of novel targeted therapies. He earned his medical degree from Johns Hopkins University School of Medicine and completed training at Dana-Farber Cancer Institute. 

The first print issue of Blood Cancer Discovery will be published early next year, and papers accepted for publication this year will be published online rapidly.  

For more information or to submit a manuscript, please visit www.AACRjournals.org/bcd. To learn about the AACR’s publication program, which spans the spectrum of cancer research, please visit www.AACRjournals.org.